Orexigen Therapeutics, Inc. (OREX) Posts Q4 Loss of 9c/Share

Orexigen Therapeutics, Inc. (NASDAQ: OREX) reported Q4 EPS of ($0.09), $0.01 better than the analyst estimate of ($0.10). Revenue for the quarter came in at $857 thousand versus the consensus estimate of $940 thousand.

For earnings history and earnings-related data on Orexigen Therapeutics, Inc. (OREX) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• JPMorgan Upgrades Aviva Plc (AV/:LN) (AIVAF) to Overweight
• HSBC Upgrades Pegatron Corp. (4938:TT) to Hold
• Goldman Sachs Upgrades Tingyi Cayman Islands Holding Corp. (322:HK) (TCYMY) to Buy